|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
2004-12-21
|
|
pubmed:abstractText |
Kaposi sarcoma (KS) in patients who are seronegative and seropositive for human immunodeficiency virus is currently the most common malignant tumor in central Africa. It accounts for 50% of all tumors reported in central African countries. Owing to the rising number of patients and the limitations of current therapies, there is an urgent demand for new strategies to treat KS.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
0003-987X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
140
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1504-7
|
|
pubmed:dateRevised |
2008-3-17
|
|
pubmed:meshHeading |
pubmed-meshheading:15611430-Adult,
pubmed-meshheading:15611430-Angiogenesis Inhibitors,
pubmed-meshheading:15611430-Cyclophosphamide,
pubmed-meshheading:15611430-Drug Therapy, Combination,
pubmed-meshheading:15611430-Endemic Diseases,
pubmed-meshheading:15611430-Humans,
pubmed-meshheading:15611430-Lactones,
pubmed-meshheading:15611430-Male,
pubmed-meshheading:15611430-Mozambique,
pubmed-meshheading:15611430-Sarcoma, Kaposi,
pubmed-meshheading:15611430-Skin Neoplasms,
pubmed-meshheading:15611430-Sulfones,
pubmed-meshheading:15611430-Thiazolidinediones,
pubmed-meshheading:15611430-Treatment Outcome
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Antiangiogenic therapy with pioglitazone, rofecoxib, and trofosfamide in a patient with endemic kaposi sarcoma.
|
|
pubmed:affiliation |
Department of Dermatology, University of Regensburg, Regensburg, Germany.
|
|
pubmed:publicationType |
Journal Article,
Case Reports
|
